Can’t Buy SpaceX Yet? Wall Street Says This $150 Stock Is the Next Best Thing. But There’s a Catch

Photo of Omor Ibne Ehsan
By Omor Ibne Ehsan Updated Published

Quick Read

  • RKLB surged 422% in one year as Wall Street's top SpaceX proxy, but analysts' $98.50 consensus implies 33% downside from current prices.

  • Peter Beck's acquisitions and an $816 million government contract position Rocket Lab for Neutron's Q4 2026 debut in an uncrowded medium-lift market.

  • A successful SpaceX IPO could reset sector valuations higher, while any Neutron delay past 2026 would flip the bull case to bearish.

  • Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Can’t Buy SpaceX Yet? Wall Street Says This $150 Stock Is the Next Best Thing. But There’s a Catch

© Evgeniyqw / Shutterstock.com

Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) has become Wall Street’s go-to substitute for SpaceX, which Polymarket traders now give a 94.6% probability of going public by June 30, 2026, and retail money chasing the space theme has to land somewhere.

Rocket Lab operates small-payload launch with Electron, hypersonic test work with HASTE, and a fast-growing Space Systems business that now makes up roughly two-thirds of revenue. CEO Peter Beck has spent two years turning a launch company into a vertically integrated defense platform, buying Geost for $325 million, agreeing to absorb Mynaric and Motiv, and locking down an $816 million Space Development Agency contract for 18 satellites.

Shares are up 422.36% over the past year, 411% year to date, and 95% in the past month alone. That is what happens when the only pure-play public alternative to SpaceX gets caught in the updraft of an imminent IPO and a Starship explosion that sent investors hunting for a backup plan.

Why the SpaceX halo is doing real work

The fundamentals are doing real work underneath the SpaceX halo. Q1 revenue hit $200.35 million, up 63.5% year over year, with non-GAAP gross margin expanding to 43.0% from 33.4% a year earlier. Backlog climbed to $2.20 billion, and the company signed 31 new Electron and HASTE contracts plus 5 Neutron missions in the quarter.

RKLB earnings explorer

Neutron is the catalyst hiding behind everything else. A successful Q4 2026 debut would put Rocket Lab in a medium-lift category currently occupied by exactly one company. Add Golden Dome, the Space Based Interceptor partnership with Raytheon, and a balance sheet carrying $1.48 billion in cash, and the bull thesis builds itself.

The catch at 121 times sales

Market cap sits near $85 billion against trailing revenue of $679.6 million, working out to a price-to-sales ratio of 121. Rocket Lab posted a $198.2 million net loss in fiscal 2025 and burned $165.5 million in operating cash flow, funded largely by $1.07 billion of fresh equity.

The analyst consensus target of $98.5 implies roughly 33% downside from current levels, even with 17 Buy or Outperform ratings against 4 Holds and zero Sells. A gap that big between current price and consensus is loud, though I’d argue the Wall Street analysts have been left behind by rapidly-rising stock.

Why patience beats conviction here

Fundamentals are improving fast, just nowhere near fast enough to justify 121 times sales on their own. A clean Neutron debut tips the picture toward Buy. Another stage-one tank issue tips it toward Sell.

RKLB is up 95% year to date against an S&P 500 running in the high single digits over the same stretch. That gap is the SpaceX IPO trade, and it will unwind once SPCX prices. Retail enthusiasm is real, with Rocket Lab ranked #2 on the WallStreetBets 2026 poll, but enthusiasm and earnings power are different inputs.

But again, just because the price is high does not mean you should always stay away. When SpaceX has its IPO and it gets successful, its ballooning valuation will be the new benchmark. RKLB’s price-sales ratio might pale in comparison.

The verdict on RKLB stock

I’ll call RKLB stock a hold if you are risk-averse, but a buy if you see a successful SpaceX IPO.

Two things have to break right for the bull case. The SpaceX IPO has to lift the whole sector rather than drain capital out of proxies, and Neutron has to fly on time. Both are possible. Neither is in your control.

The bear case requires valuation to matter before the catalyst arrives. Shorting a retail-favorite stock eight weeks before a SpaceX roadshow is its own kind of gamble.

The setup is one where existing exposure looks defensible and fresh exposure looks expensive. The catalysts worth tracking are a clean Neutron static fire in Q3 and an orderly SpaceX listing that lifts rather than cannibalizes the sector. The downside catalysts are any Neutron slip past 2026 or a Q2 earnings report that shows backlog growth stalling.

The picture clarifies once Neutron flies and the SpaceX listing actually happens, which is when the market will decide what kind of stock this really is.

 

Photo of Omor Ibne Ehsan
About the Author Omor Ibne Ehsan →

Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks.

Continue Reading

Top Gaining Stocks

KMX Vol: 7,325,322
GLW Vol: 22,199,064
INTC Vol: 230,355,973
SMCI Vol: 67,974,771
ENPH Vol: 13,822,735

Top Losing Stocks

ACN Vol: 41,659,419
EPAM Vol: 5,609,217
CTSH Vol: 60,753,691
CTRA Vol: 73,319,495
KR Vol: 26,633,125